HIV can develop resistance to blockbuster antiviral lenacapavir—but at a cost to the virus

Long-acting antiviral medications are transforming HIV prevention and care, requiring only minimalistic dosing. But as the use of lenacapavir expands, scientists are probing a critical question: If the virus evolves resistance, does it also pay a cost?

Continue Reading this article here